Search Medical Condition
Please enter condition
Please choose location from dropdown

Chang Chun, China Clinical Trials

A listing of Chang Chun, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (238) clinical trials

Survival Study of the Recombinant Human Neuregulin-1 in Subjects With Chronic Heart Failure.

The mortality of chronic heart failure patients remains high, in spite of current treatment. RhNRG-1(recombinant human neuregulin-1)directly work on the cardiomyocyte and restored the normal structure and function of it. Both the preclinical trials, phase II clinical trials and already completed phase III clinical trails have confirmed that rhNRG-1 effectively ...

Phase

0.0 miles

Learn More »

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.

Phase

0.0 miles

Learn More »

China Cognition and Aging Study

This study involved participants including amnestic mild cognitive impairment (aMCI), sporadic Alzheimer's disease (SAD), familial Alzheimer's disease (FAD), Vascular cognitive impairment (VCI), and APOE gene cohort (cognitive normal subjects). Research contents are as follow Neuropsychological characteristics of Chinese aMCI, SAD, VCI: analyze the cognitive function, daily living ability and mental ...

Phase N/A

0.0 miles

Learn More »

The Chinese Familial Alzheimer's Network

Set up a multi-center, national-wide FAD research network and electronic database platform in China, including ADAD cohort of the known mutations PSEN1, PSEN2 and APP (mutation carriers and noncarriers; presymptomatic and symptomatic) and unknown mutation cohort. Clarify the genetic characteristic of familial Alzheimer's disease, and find risk and protective genes ...

Phase N/A

0.0 miles

Learn More »

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Approximately 110 participants will be assigned to SHR-1210 + capecitabine + oxaliplatin combination therapy (Cohort 1), or SHR-1210 + apatinib combination therapy (Cohort 2).

Phase

0.0 miles

Learn More »

Predictive Value of Inflammatory Biomarkers and FEV1 for COPD

This is a multi-center, prospective, cohort study. A total of 10,000 subjects aged 4075 without history of lung disease will be recruited and followed for 3 years. The Department of Respiratory and Critical Care of Peking University First Hospital is responsible for this research. Other 9 units participating in the ...

Phase N/A

0.0 miles

Learn More »

Coil System(Ton-bridgeMT) for Endovascular Embolization of Cranial Aneurysms

The study is a prospective, multi-center, randomized, open, parallel positive control, non-inferiority trial. Patients are randomized 1:1 to either Coil System(Ton-bridgeMT) or Axium Detachable Coil(Medtronic). The purpose of this study is to assess the safety and effectiveness of the Coil System(Ton-bridgeMT) in the treatment of intracranial aneurysms.

Phase N/A

0.0 miles

Learn More »

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

This is an Asian multi-regional clinical trial (MRCT) in which ATG-008 will be administered orally to hepatitis B positive (HBV+) HCC subjects who have received at least one prior line of systemic therapy. It is designed as an open-label phase 2 trial evaluating the pharmacokinetics (PK), safety, tolerability and efficacy ...

Phase

0.0 miles

Learn More »

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

Phase

0.0 miles

Learn More »

Efficacy and Safety of rhGH (Jintropin ) in Pediatric Participants With ISS

Phase 1: To evaluate the safety and efficacy of 0.05mg/kg/d of rhGH (Jintropin) in the treatment of children with idiopathic short stature (ISS) in 52 weeks. Phase 2: To evaluate the safety and efficacy of rhGH (Jintropin) in the treatment of children with ISS in 2 years

Phase

0.0 miles

Learn More »